Jon Edwards Ph.D Overview

  • Primary Position
  • Executive

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 4

  • Med. Deal Size

  • Med. Valuation

Jon Edwards Ph.D General Information

Biography

Dr. Jon Edwards serves on the Board of Directors at Curebound. He served as Senior Advisor at Red Tree Venture Capital. He served as a Board Member at Rondo Therapeutics. He is a Managing Director at Red Tree Venture Capital and part of the founding investment team. Prior to joining Red Tree, he helped found Medicxi (a therapeutics-focused venture fund) where he was most recently a partner in the London office. He began his venture capital career at Index Ventures in Switzerland. Before moving to Europe, Jon was a life sciences strategy consultant at ClearView Healthcare Partners based in Boston. His investments include Synthorx (acquired by Sanofi), Phathom Pharmaceuticals (NASDAQ: PHAT), Checkmate Pharmaceuticals (NASDAQ: CMPI), Impact Biomedicines (acquired by Celgene), Sydnexis Inc., Xenikos B.V., and Breakpoint Therapeutics Gmbh. He has also held board seats on Z-Factor Ltd. (NASDAQ: CNTA), UltraHuman Ltd., and Palladio Biosciences (NASDAQ:CNTA) and was a board observer with ApcinteX Ltd. (NASDAQ: CNTA) and Capella Bioscience (NASDAQ: CNTA). He received a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and holds a B.S. from the University of Vermont. He also spent time at the bench at Sepracor, Inc. and conducted his postdoctoral research at MIT. He serves as a Board Member at Sardona Therapeutics. He served as a Board Member at Excellergy Therapeutics. He also served as a Board Member at Virsti Therapeutics. He served as a Board Member at Sydnexis. He served as a Partner at Medicxi. He served as a Board member at Palladio Biosciences. He served as a Board Member at UltraHuman. Prior to Medicxi Ventures, he worked at Index as an Associate for two years. Before that, he worked as a life science strategy consultant at ClearView Healthcare Partners. He is an observer on the board of directors of Ultrahuman, Capella Bioscience, and Apcintex. He obtained his Ph.D. in biochemistry and biophysics from UNC Chapel Hill and also conducted postdoctoral research at MIT, where he is an affiliate in the Department of Biological Engineering. He also served as a Board Member at Phathom Pharmaceuticals. He serves as Board Member at Catalym. Jon recently joined the Bioqube Ventures team. Previously, he served as Managing Director at Red Tree Venture Capital and was part of the founding team at Medicxi where he was a partner in the London office. He has led multiple investments spanning company formation, syndicated deals, and late-stage crossover/IPO financings. A few notable investments include Impact Biomedicines (acquired by Celgene), Synthorx (acquired by Sanofi), Phathom Pharmaceuticals (NASDAQ:PHAT), and Checkmate Pharmaceuticals (acquired by Regeneron). Jon conducted his postdoctoral research at MIT and holds a PhD in Biochemistry and Biophysics from the University of North Carolina - Chapel Hill.

Contact Information

Primary Position
Executive, Bioqube Ventures
Education
University of North Carolina, Chapel Hill, Ph.D. (Doctor of Philosophy)
University of Vermont, BS (Bachelor of Science)
Gender
Male
Email
jo
Address
  • Barricadenplein 13
  • 1000 Brussels
  • Belgium

Jon Edwards Ph.D Positions (1)

Firm name Firm type Title Location Industry Since
Bioqube Ventures Investor Executive Brussels, Belgium Venture Capital

Jon Edwards Ph.D Board Seats (4)

Company Industry Ownership Status Financing Status Location Since
Catalym Drug Discovery Privately Held (backing) Venture Capital-Backed Planegg, Germany
Curebound San Diego, CA
Sardona Therapeutics Discovery Tools (Healthcare) Privately Held (backing) Venture Capital-Backed San Francisco, CA
Xenikos Drug Discovery Privately Held (backing) Venture Capital-Backed Nijmegen, Netherlands

Jon Edwards Ph.D Lead Partner on Deals (9)

Jon Edwards Ph.D has been the lead partner on 9 deals. Their latest deal was with SynOx Therapeutics, a drug discovery company. The deal was made for on 30-Oct-2024.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
SynOx Therapeutics 30-Oct-2024 Early Stage VC (Series B) Completed Drug Discovery Dublin, Ireland
Catalym 16-Jul-2024 Completed Drug Discovery Planegg, Germany
Excellergy Therapeutics 06-Oct-2022 Completed Drug Discovery Redwood City, CA
Rondo Therapeutics 22-Feb-2022 Completed Biotechnology Hayward, CA
Breakpoint Therapeutics 08-Jul-2019 Completed Drug Discovery Hamburg, Germany
Phathom Pharmaceuticals 15-May-2019 Completed Biotechnology Florham Park, NJ
Xenikos 15-May-2018 Completed Drug Discovery Nijmegen, Netherlands
Palladio Biosciences 26-Jul-2016 Early Stage VC (Series A) Completed Drug Discovery Horsham, PA
Sardona Therapeutics Early Stage VC Completed Discovery Tools (Healthcare) San Francisco, CA

Jon Edwards Ph.D Network (156)

Board Members (89)

Name Company Representing Location From
Mark Stenhouse Phathom Pharmaceuticals Self Florham Park, NJ
Colleen Cuffaro Ph.D Catalym Canaan Partners Planegg, Germany
Curebound Self San Diego, CA
Phathom Pharmaceuticals Phathom Pharmaceuticals Florham Park, NJ
Catalym BioGeneration Ventures Planegg, Germany

Portfolio Executives (54)

Name Company Role Deal date Location
Robert Francomano SynOx Therapeutics Chief Commercial Officer 30-Oct-2024 Dublin, Ireland
Axel Mescheder MD SynOx Therapeutics Chief Medical Officer 30-Oct-2024 Dublin, Ireland
SynOx Therapeutics Chief Medical Officer 30-Oct-2024 Dublin, Ireland
SynOx Therapeutics Chief Executive Officer & Board Member 30-Oct-2024 Dublin, Ireland
SynOx Therapeutics Senior Vice President of Finance and Administration 30-Oct-2024 Dublin, Ireland

Fund Team Members (13)

Name Investor Fund Fund Location
Samad Wahid MD Red Tree Venture Capital Red Tree Venture Fund Redwood City, CA
Jennifer Cochran Ph.D Red Tree Venture Capital Red Tree Venture Fund Redwood City, CA
Medicxi London, United Kingdom
Medicxi London, United Kingdom
Medicxi London, United Kingdom

Jon Edwards Ph.D Affiliated Funds (3)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
Medicxi Growth I Medicxi Venture - General Closed 2017
Red Tree Venture Fund Red Tree Venture Capital Venture Capital - Early Stage Closed 2022
Medicxi Ventures 1 Medicxi Venture - General Closed 2016

Jon Edwards Ph.D FAQs

  • Who is Jon Edwards Ph.D?

    Dr. Jon Edwards serves on the Board of Directors at Curebound.

  • How much does Jon Edwards Ph.D typically invest?

    Jon Edwards Ph.D's median deal size is .

  • What is Jon Edwards Ph.D’s main position?

    Jon Edwards Ph.D’s primary position is Executive.

  • How many active board seats does Jon Edwards Ph.D hold?

    Jon Edwards Ph.D holds 4 board seats including Catalym, Curebound, Sardona Therapeutics, and Xenikos.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »